ARS Pharmaceuticals Inc [NASDAQ: SPRY] closed the trading session at $10.69 on 2025-09-04. The day’s price range saw the stock hit a low of $10.33, while the highest price level was $11.0263.
The stocks have a year to date performance of -17.64 percent and weekly performance of -20.46 percent. The stock has been moved at -1.66 percent over the last six months. The stock has performed -39.94 percent around the most recent 30 days and changed -22.65 percent over the most recent 3-months.
If compared to the average trading volume of 1.78M shares, SPRY reached to a volume of 4264355 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about ARS Pharmaceuticals Inc [SPRY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SPRY shares is $32.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SPRY stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Roth Capital have made an estimate for ARS Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 04, 2025. While these analysts kept the previous recommendation, Scotiabank raised their target price to Sector Outperform. The new note on the price target was released on March 07, 2025, representing the official price target for ARS Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $40, while Oppenheimer analysts kept a Outperform rating on SPRY stock.
The Price to Book ratio for the last quarter was 5.49, with the Price to Cash per share for the same quarter was set at 2.43.
SPRY stock trade performance evaluation
ARS Pharmaceuticals Inc [SPRY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -20.46. With this latest performance, SPRY shares dropped by -39.94% in over the last four-week period, additionally sinking by -1.66% over the last 6 months – not to mention a rise of 1.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SPRY stock in for the last two-week period is set at 22.01, with the RSI for the last a single of trading hit 0.85, and the three-weeks RSI is set at 0.86 for ARS Pharmaceuticals Inc [SPRY]. The present Moving Average for the last 50 days of trading for this stock 16.21, while it was recorded at 11.43 for the last single week of trading, and 13.83 for the last 200 days.
ARS Pharmaceuticals Inc [SPRY]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and ARS Pharmaceuticals Inc [SPRY] shares currently have an operating margin of -52.82% and a Gross Margin at 93.56%. ARS Pharmaceuticals Inc’s Net Margin is presently recorded at -42.74%.
ARS Pharmaceuticals Inc (SPRY) Capital Structure & Debt Analysis
According to recent financial data for ARS Pharmaceuticals Inc. ( SPRY), the Return on Equity (ROE) stands at -23.56%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -17.94%, reflecting the company’s efficiency in generating profits from its assets. Additionally, ARS Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -24.83%, showcasing its effectiveness in deploying capital for earnings.
ARS Pharmaceuticals Inc (SPRY) Efficiency & Liquidity Metrics
Based on ARS Pharmaceuticals Inc’s (SPRY) latest financial statements, the Debt-to-Equity Ratio is 0.01%, indicating its reliance on debt financing relative to shareholder equity.
ARS Pharmaceuticals Inc (SPRY) Efficiency & Liquidity Metrics
From an operational efficiency perspective, ARS Pharmaceuticals Inc. (SPRY) effectively leverages its workforce, generating an average of -$300125.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 6.17% and a Quick Ratio of 5.98%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for ARS Pharmaceuticals Inc [SPRY] stock
With the latest financial reports released by the company, ARS Pharmaceuticals Inc posted -0.2/share EPS, while the average EPS was predicted by analysts to be reported at -0.14/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.06. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SPRY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for ARS Pharmaceuticals Inc go to 49.78%.
ARS Pharmaceuticals Inc [SPRY]: Institutional Ownership
There are presently around $86.21%, or 103.66%% of SPRY stock, in the hands of institutional investors. The top three institutional holders of SPRY stocks are: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) with ownership of 11.08 million shares, which is approximately 11.4409%. RA CAPITAL MANAGEMENT, L.P., holding 10.86 million shares of the stock with an approximate value of $$92.43 million in SPRY stocks shares; and RA CAPITAL MANAGEMENT, L.P., currently with $$78.64 million in SPRY stock with ownership which is approximately 9.5436%.
